Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05573100 · ClinicalTrials.gov registry record · Phase 2
The Study of CU06-1004 in Patients With Diabetic Macular Edema (DME)
A Phase 2 study, sponsored by Curacle Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT05573100 is a Phase 2 study that has completed, run by Curacle Co.. The registered enrollment target is 67 participants.
The verdict
NCT05573100, a Phase 2 study, has completed, sponsored by Curacle Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
This phase 2a trial is a randomized, open-label, parallel-group study in approximately 60 patients with DME to evaluate the efficacy and safety of CU06-1004 orally administered once daily for 12 weeks. The study will have a 1:1:1 randomization (CU06-1004 100mg: CU06-1004 200mg: CU06-1004 300mg).
Interventions
- DRUG CU06-1004
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2022-12-21 |
| Est. Completion | 2023-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05573100
The ClinicalTrials.gov registry entry for NCT05573100 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Curacle Co., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CU06-1004 is the first listed.
NCT05573100 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05573100 about?
NCT05573100 is a clinical study titled "The Study of CU06-1004 in Patients With Diabetic Macular Edema (DME)". This phase 2a trial is a randomized, open-label, parallel-group study in approximately 60 patients with DME to evaluate the efficacy and safety of CU06-1004 orally administered once daily for 12 weeks. The study will have a 1:1:1 randomization (CU06-1004 100mg: CU06-1004 200mg: CU06-1004 300mg).
What is the current status of trial NCT05573100?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2022-12-21. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT05573100?
The interventions under investigation include: CU06-1004 (DRUG).
Who is sponsoring clinical trial NCT05573100?
This trial is sponsored by Curacle Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.